All-told the Mayo Clinic’s recent pilot study on clinical trial patient recruitment using social media and online networks not only helped researchers assemble large and demographically diverse patient groups more quickly, but also less expensively than they could through other means
All-told the Mayo Clinic’s recent pilot study on clinical trial patient recruitment using social media and online networks not only helped researchers assemble large and demographically diverse patient groups more quickly, but also less expensively than they could through other means.
“This study is a prime example of patient-initiated research that could be used by other health care professionals and institutions,” conclude the authors of the Mayo report.
But can the Mayo Clinic’s pilot study really be used “by other health care professionals and institutions”? Was the success of their social media recruitment so easily translatable? Or was their pilot study the result of a perfect storm-a series of factors coming together to make it just the right opportunity for social media recruitment, and anything but commonplace?
What made it a Perfect Storm?
In an article in Digital Strategy & Patient Recruitment for Clinical Trials, Rahlyn Gossen examines key patient recruitment factors that resulted in the Mayo’s pilot study’s success and a perfect social media fit. A former clinical research coordinator who now has her own firm, Rebar Interactive, Gossen lists these six factors:
“In some cases, clinical research professionals can mimic the factors contributing to Mayo’s success,” says Gossen. “But in most cases, the possibility for successful social media recruitment will largely be the result of static factors like therapeutic indication, patient population, study design, and geography.”
“Before undertaking a social media campaign for patient recruitment, it’s imperative that clinical research professionals identify pertinent variables and determine whether those variables are well-aligned with a social media recruitment campaign,” says Gossen.
It is also imperative that whomever is behind the effort is equipped with the social media skills enjoyed by the Mayo Clinic (you only have to go to their website for a glimpse of their media expertise and sense of design). They must also be motivated by more than just a desire to sell a social media service.
“The reality is that, in many cases, patient recruitment via social media will be an uphill battle,” says Gossen. “But all is not lost. You can still recruit patients who frequent social media sites with advertising on those sites, thereby eliminating the challenges of patient recruitment on social media websites.”
Gossen told Applied Clinical Trials that it is important to distinguish between social media and advertising on social media platforms. “Social media is by nature a dialogue and requires a very different strategy and skill set than online advertising, which is more of a one-way broadcasting medium. An example of this distinction in practice is the difference between, say, putting up a Facebook page and conversing with those who are commenting versus putting up ads on Facebook. This distinction, I’ve noticed, is unclear regarding terminology.”
A tactical advertisement on Facebook, however, can be targeted among the site’s hundreds of millions of users. Its offerings for advertisers also can be highly targeted to specific geographic areas. And with such a large population, Facebook can reach a high percentage of potential patients across all levels of income and education. Traditional media can’t even touch those results.
Nevertheless, the uphill battle in social media recruitment was confirmed last spring by a survey conducted by Blue Chip Patient Recruitment. The study found: Of 179 adults who were queried through postings in online health communities, 84 percent have never participated in a trial. Twenty-two percent would enroll if a drug offered a cure and 21 percent if they could help find a cure.
Online or offline, safety also presented an issue to the survey participants:
And when asked where they would first go to learn more about a trial:
For those invested heavily in the favorite social media sites:
In the end, using social media for patient recruitment is perhaps not so much an uphill battle as an exercise in strategy, discernment, and selection. It can work, it can even be an ideal method (as seen in the Mayo Clinic pilot study), but the particular conditions of the study must fit the social media opportunity, and not the other way around.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
2 Commerce Drive
Cranbury, NJ 08512